Therapeutic potential of CAR T cell in malignancies: A scoping review - 16/01/22
pages | 11 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Although tremendous advancements in cancer therapy over the last several years, cancer still is a complex illness to cure. Traditional cancer treatments, including chemotherapy, radiotherapy, and surgery, have a poor therapeutic effect, emphasizing the significance of employing innovative treatments like activated cell therapy. Chimeric antigen receptor T cell is one of the most prevalent types of activated cell therapy have been developed to direct T lymphocytes toward cancers (CAR-T cells). CAR-T cells therapy has illustrated poor impact versus solid tumors despite the remarkable success in patients suffering from hematological malignancies. CAR-T cells must overcome various hurdles to obtain full responses to solid tumors, including growth, stability, trafficking, and destiny inside tumors. As a result, novel treatment methods will entail overcoming the challenges that CAR-T cells face in solid tumors. The use of CAR-T cells in combination with other therapeutic approaches such as chemotherapy, radiotherapy, immuno-checkpoint inhibitors, and oncolytic viruses can promote the effectiveness of CAR-T cell therapy for the treatment of solid tumors. However, more research is needed to determine the safety and effectiveness of these therapies. CAR-T cell treatment success rates vary by type of disease, but are predicted to reach up to 90% in patients with leukemia. However, since this kind of immunotherapy is still in its infancy, there is much to learn about its efficacy. This review provided an in-depth examination of CAR-T cell therapy and its success and failure as a cancer treatment approach. We also discuss combination therapies with CAR-T Cell.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | CAR-T cell therapy is one of several treatments included in cancer immunotherapy. |
• | CAR T cells have been categorized into fifth distinct generations. |
• | CAR-T cell therapy is not entirely safe, and this strategy has notable limitations. |
• | Combination therapies improve the function of CAR-T cell efficiency in solid tumors. |
Keywords : Chimeric antigen receptor T cells (CAR-T cells), Toxicities, Oncolytic viruses, Clinical trial, Combinational therapies
Plan
Vol 146
Article 112512- février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?